Sarin

Revive Therapeutics Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
DRDC, Neuroprotection, Tremor, Diazepam, Chronic pain, COVID, Soman, National security, Survival, NAC, Seizure, Partnership, Nervous system, VX, COVID-19, Nerve agent, Patient, Brain, Heart rate, Research, Diarrhea, Endocytosis, RVV, Death, Doctor of Philosophy, Health Canada, Trial of the century, Cough, Traumatic brain injury, CDC, Harvard University, Fever, Sarin, Bleeding, Safety, Chemical warfare, Saliva, Therapy, Disorder, Blurred vision, FDA, Economics, Nerve, Hospital, Pharmaceutical industry

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.

Key Points: 
  • TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.
  • Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.
  • In addition, Revive may evaluate the potential of its proposed long COVID diagnostic product as a companion to Bucillamine.
  • The Company, under its wholly-owned subsidiary Revive Diagnostics Inc., is advancing the product development of a potential blood biomarker diagnostic that characterizes long COVID.

Enhancing National Preparedness: Rafa Laboratories Partners with BARDA to Advance the Development of a new design for Rafa's Pediatric Atropine Autoinjectors

Retrieved on: 
Wednesday, March 20, 2024
Development, Poisoning, Organophosphate, VX, Status epilepticus, Patient, Nerve agent, Clothing, Laboratory, Human services, Atropine, Sarin, Administration, FDA

Atropine - the primary antidote for nerve agent and insecticide poisoning, is usually administered via autoinjectors.

Key Points: 
  • Atropine - the primary antidote for nerve agent and insecticide poisoning, is usually administered via autoinjectors.
  • Rafa Laboratories already manufactures adult atropine autoinjectors, FDA-approved in July 2018, and pediatric atropine autoinjectors authorized for use under FDA Emergency Use Authorization (EUA) in January 2018.
  • The new design for the pediatric atropine autoinjector, which is intended for civilian use, will incorporate a new needle shield mechanism feature.
  • To meet FDA approval requirements for the enhanced pediatric atropine autoinjector, BARDA will provide comprehensive support to Rafa Laboratories.

Enhancing National Preparedness: Rafa Laboratories Partners with BARDA to Advance the Development of a new design for Rafa's Pediatric Atropine Autoinjectors

Retrieved on: 
Wednesday, March 20, 2024
Development, Poisoning, Organophosphate, VX, Status epilepticus, Patient, Nerve agent, Clothing, Laboratory, Human services, Atropine, Sarin, Administration, FDA

Atropine - the primary antidote for nerve agent and insecticide poisoning, is usually administered via autoinjectors.

Key Points: 
  • Atropine - the primary antidote for nerve agent and insecticide poisoning, is usually administered via autoinjectors.
  • Rafa Laboratories already manufactures adult atropine autoinjectors, FDA-approved in July 2018, and pediatric atropine autoinjectors authorized for use under FDA Emergency Use Authorization (EUA) in January 2018.
  • The new design for the pediatric atropine autoinjector, which is intended for civilian use, will incorporate a new needle shield mechanism feature.
  • To meet FDA approval requirements for the enhanced pediatric atropine autoinjector, BARDA will provide comprehensive support to Rafa Laboratories.

Sprinklr to Present at Barclays Global Technology Conference

Retrieved on: 
Friday, November 17, 2023
Technology, Professional Services, Public Relations, Investor Relations, Marketing, Communications, Social Media, Software, Artificial Intelligence, Internet, Mobile, Wireless, Finance, CXM, Fireside chats, Sarin, NYSE, Fireside, Network equipment provider, Self storage

Sprinklr (NYSE: CXM), the unified customer experience management (Unified-CXM) platform for modern enterprises, today announced that Manish Sarin, Sprinklr’s Chief Financial Officer, will be participating in a Fireside Chat at the following investor event:

Key Points: 
  • Sprinklr (NYSE: CXM), the unified customer experience management (Unified-CXM) platform for modern enterprises, today announced that Manish Sarin, Sprinklr’s Chief Financial Officer, will be participating in a Fireside Chat at the following investor event:
    A live audio webcast and replay will be available on Sprinklr’s investor relations website: https://investors.sprinklr.com/ and archived for a period of 90 days.

PyroGenesis Announces $360,000 Initial Contract for a Plasma-Based PACWAD System for Chemical Warfare Waste Destruction

Retrieved on: 
Tuesday, October 24, 2023
Sarin, 0 A.D. (video game), Plasma, Conventional weapon, FRA, Pollution, Soman, ICEX: US Navy Mission in Arctic, Farm, Wind, Mustard gas, Transport, Mineral, Client, USS Gerald R. Ford, GHG, VX, United States Navy, Forest Law Enforcement and Governance Program, European, Greenhouse, TSX, Renewable energy, Environmental remediation

The contract includes a 45% upfront payment of the total contract value, or 112,500 € (approximately CA$160,000), which has already been received.

Key Points: 
  • The contract includes a 45% upfront payment of the total contract value, or 112,500 € (approximately CA$160,000), which has already been received.
  • Under this agreement, as part of a potential three-phase project PyroGenesis will first provide a lab-scale size plasma arc chemical warfare agent destruction system (the “PACWADS”) as part of a multi-partner project aimed at identifying, extracting, and disposing of chemical munitions and chemical warfare agents residing in active marine passageways and corridors.
  • The eventual goal is to develop a full-scale system once results from the lab-scale system are reviewed.
  • Plasma torches as a waste destruction application are part of the Company’s Waste Remediation tier, encompassing the safe destruction of hazardous materials, and the recovery and valorization of underlying substances such as chemicals and minerals.

CFOs of Marriott, AstraZeneca, Kroger Honored by Peers in First Annual CFO Leadership Awards

Retrieved on: 
Tuesday, October 10, 2023
Diamond, Team leader, AWS, Sarin, Kroger, Marriott International, Intel, Digital, Amazon Web Services, Bank of America, AstraZeneca, Award, Growth, Nasdaq MarketSite, Bank, CFO, EVP, Starbucks, Research, AlixPartners, Management, Humana, Oracle

A team from AlixPartners served as the exclusive advisor to the committee in its research and decision-making process.

Key Points: 
  • A team from AlixPartners served as the exclusive advisor to the committee in its research and decision-making process.
  • The Awards will be presented live on Dec. 4, 2023, at the annual Strategic CFO Forum, hosted at the Nasdaq MarketSite in New York City.
  • (More about the event: StrategicCFO360.com/StrategicCFOForum )
    The 2023 CFO Leadership Awards Selection Committee includes: Alastair Borthwick, CFO, Bank of America; Susan Diamond, CFO, Humana; Jeff Epstein, operating partner, Bessemer Venture Partners, former CFO, Oracle; Carolina Dybeck Happe, CFO, GE; Richard Puccio, CFO, Amazon Web Services; Rachel Ruggeri, CFO, Starbucks; Tracey Travis, EVP and CFO, The Estée Lauder Companies; Dave Zinsner, CFO, Intel Corporation.
  • AlixPartners serves as the exclusive advisor to the selection committee for all of these awards.

Sprinklr to Present at Upcoming Investor Conference

Retrieved on: 
Wednesday, August 16, 2023
Technology, Professional Services, Public Relations, Investor Relations, Marketing, Communications, Social Media, Software, Artificial Intelligence, Internet, Mobile, Wireless, Finance, Fireside chats, NYSE, Sarin, CXM, Fireside, Sprinklr

Sprinklr (NYSE: CXM), the unified customer experience management (Unified-CXM) platform for modern enterprises, today announced that Manish Sarin, Sprinklr’s Chief Financial Officer, will be participating in a Fireside Chat at the following event:

Key Points: 

American Red Cross Elects Aradhana Sarin as New Member to National Board of Governors

Retrieved on: 
Thursday, July 13, 2023
American Red Cross, Board of Governors of the United States Postal Service, JPMorgan Chase, Physician, Health care, AstraZeneca, Investment, International Red Cross and Red Crescent Movement, Annual general meeting, Red, Alexion, UBS, Red Cross, National Board of Medical Examiners, Sarin, Nursing, Management

WASHINGTON, July 13, 2023 /PRNewswire/ -- The American Red Cross elects to its National Board of Governors, Dr. Aradhana Sarin, chief financial officer and executive director, AstraZeneca PLC.

Key Points: 
  • WASHINGTON, July 13, 2023 /PRNewswire/ -- The American Red Cross elects to its National Board of Governors, Dr. Aradhana Sarin, chief financial officer and executive director, AstraZeneca PLC.
  • "We are thrilled to welcome Dr. Aradhana Sarin to the Red Cross Board of Governors.
  • "Aradhana's experience will be valuable in helping us to carry out the humanitarian mission of the American Red Cross."
  • At the Annual Meeting of the Red Cross held on July 12, 2023, delegates from local Red Cross units elected Dr. Sarin to a three-year term.

Sprinklr to Host Investor Day on July 12, 2023

Retrieved on: 
Wednesday, June 14, 2023
Technology, Professional Services, Public Relations, Investor Relations, Marketing, Communications, Social Media, Software, Artificial Intelligence, Internet, Mobile, Wireless, Finance, NYSE, Sarin, CXM, Cryptocurrency, Management, Sprinklr

Sprinklr (NYSE: CXM), the unified customer experience management (Unified-CXM) platform for modern enterprises, today announced that it will hold an Investor Day on July 12, 2023 at the New York Stock Exchange in New York.

Key Points: 
  • Sprinklr (NYSE: CXM), the unified customer experience management (Unified-CXM) platform for modern enterprises, today announced that it will hold an Investor Day on July 12, 2023 at the New York Stock Exchange in New York.
  • The Sprinklr Investor Day presentation will begin at 10:00 a.m. Eastern Time and is expected to conclude at 1:00 p.m. Eastern Time.
  • Sprinklr executives presenting at the event will include Chief Executive Officer, Ragy Thomas, and Chief Financial Officer, Manish Sarin, along with several other members of the leadership team and Sprinklr customers who will provide an overview of the company’s market opportunities, new product innovations, various use cases, and Sprinklr’s financial outlook.

Cerence Adds Former Ford Executive Marcy Klevorn to its Board of Directors

Retrieved on: 
Thursday, June 1, 2023
CRNC, University, EVP, Ford, Business, Ford Motor Company, Investment, CIO, AI, Transport, Sarin, Management, Humana

In her more than 35-year career at Ford, Ms. Klevorn held varying executive and leadership roles within the company’s information technology organization, including global Chief Information Officer (CIO) and, previously, CIO of Ford Motor Company in Europe.

Key Points: 
  • In her more than 35-year career at Ford, Ms. Klevorn held varying executive and leadership roles within the company’s information technology organization, including global Chief Information Officer (CIO) and, previously, CIO of Ford Motor Company in Europe.
  • In this role, she also chaired the board of Ford Autonomous Vehicles LLC.
  • “Marcy is a known and respected leader who brings a wealth of experience in automotive and mobility to her role on the Cerence Board of Directors,” said Arun Sarin, Chairman of the Board of Directors, Cerence.
  • “I am honored to join Cerence’s Board of Directors at this exciting time in the company’s journey,” said Marcy Klevorn.